Ушбу ишга иқтибос қилган ишлар

2 та иш

Иш: Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study

1. Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology

   Jinxin Dong, Denis Nikolenko, Shuxrat Boymuradov +2

   МақолаCAR-T cell therapy researchClinical & Translational Oncology20261 иқтибос

   ABIABI:AkademIndex/openalex/2026.article.000172

2. Innovations in cancer immunotherapy: A comprehensive overview of recent breakthroughs and future directions

   Chou‐Yi Hsu, Harikumar Pallathadka, Saade Abdalkareem Jasim +7

   Шарҳ мақолаCAR-T cell therapy researchCritical Reviews in Oncology/Hematology20240 иқтибос

   ABIABI:AkademIndex/openalex/2024.review-article.000011